--- title: "Phio Pharmaceuticals (PHIO) news: going concern and offering" url: "https://aibio.space/companies/phio-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PHIO going concern and offering news: Phio Pharmaceuticals sets up $6,360,000 at-the-market program. Phio Pharmaceuticals Corp." --- PHIO Phio Pharmaceuticals Corp. NASDAQ · United States # Phio Pharmaceuticals (PHIO) news PHIO going concern and offering news Company Updates · 2026-10-13 ## [Phio completes first commercial-scale cGMP batch of PH-762 drug substance](https://aibio.space/news/phio-completes-first-commercial-scale-cgmp-batch-ph-762-drug-substance/) The batch is a manufacturing milestone that supports the planned start of a Phase 2b trial in the first quarter of 2027. The company issued a press release announcing it on October 13, 2026. ## Latest Phio Pharmaceuticals news 1. 2026-09-14 Company Updates [Phio reports PH-762 FDA submission and planned Phase 2b study](https://aibio.space/news/phio-reports-ph-762-fda-submission-planned-phase-2b-study/) Phio Pharmaceuticals said on September 14, 2026 that it reached a development milestone for PH-762, including the submission of materials to the FDA and a planned Phase 2b neoadjuvant study. 2. 2026-07-21 Company Updates [Phio adds dermatologist R. Todd Plott to its board](https://aibio.space/news/phio-adds-dermatologist-r-todd-plott-board/) Phio Pharmaceuticals increased its board to six members and appointed R. Todd Plott, M.D., effective July 20, 2026, to serve until the 2026 annual meeting of stockholders. 3. 2026-04-08 Financings [Phio Pharmaceuticals sets up $6,360,000 at-the-market program](https://aibio.space/news/phio-pharmaceuticals-sets-up-6-360-000-market-program/) Phio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt. 4. 2025-11-06 Financings [Phio Pharmaceuticals warrant inducement brings in approximately $12.6 million at initial closings](https://aibio.space/news/phio-pharmaceuticals-warrant-inducement-brings-approximately-12-6/) Holders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees. 5. 2025-01-17 Financings [Phio Pharmaceuticals closes registered direct offering with warrants, nets about $1.6 million](https://aibio.space/news/phio-pharmaceuticals-closes-registered-direct-offering-warrants-nets/) Phio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee. ## Phio Pharmaceuticals at a glance - **Ticker**: PHIO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $13.0 million ### Related companies - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) NASDAQ: CGTX - [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) OTC: PARD - [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) NASDAQ: TVRD - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX ### Also on NASDAQ - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) RACC - [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) PTCT - [Biogen](https://aibio.space/companies/biogen/) BIIB - [BioNexus Gene Lab](https://aibio.space/companies/bionexus-gene-lab/) BGLC - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) ELVN ## What Phio Pharmaceuticals does Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL small interfering RNA gene silencing technology. INTASYL compounds are chemically modified siRNAs designed to silence genes that tumors use to evade the immune system, and the company says they can be delivered to a broad range of cell types without specialized formulations or delivery systems. Its lead compound, PH-762, is designed to reduce PD-1 expression and is being evaluated in a U.S. multi-center Phase 1b trial using intratumoral injection in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The study was fully enrolled in November 2025 with 22 patients, and an FDA submission on next steps in clinical study design is targeted for the second quarter of 2026. A second compound, PH-894, is designed to silence BRD4. The company has completed the IND-enabling studies for PH-894 but elected to defer its IND submission while it advances PH-762 in the U.S. | Product or program | What it is | Stage | |---|---|---| | PH-762 | INTASYL compound designed to reduce PD-1 expression, given by intratumoral injection | Phase 1b trial fully enrolled November 2025; FDA submission targeted second quarter 2026 | | PH-894 | INTASYL compound designed to silence BRD4 in T cells and tumor cells | IND-enabling studies completed; IND submission deferred | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm). ## Phio Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | | Net income (loss) | [-$8.7 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | [-$7.2 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | | Cash from operations | [-$8.0 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | [-$7.1 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | | Cash and equivalents | [$21.0 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926026271/) | [$5.4 million](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Phio Pharmaceuticals Has Phio Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Apr 8, 2026: "Phio Pharmaceuticals sets up $6,360,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/phio-pharmaceuticals-sets-up-6-360-000-market-program/). Has Phio Pharmaceuticals raised money recently? Our latest story on this, dated Apr 8, 2026: "Phio Pharmaceuticals sets up $6,360,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/phio-pharmaceuticals-sets-up-6-360-000-market-program/). What is the ticker symbol of Phio Pharmaceuticals? Phio Pharmaceuticals Corp. trades under the ticker PHIO on NASDAQ. Where is Phio Pharmaceuticals listed? Phio Pharmaceuticals Corp. is listed on NASDAQ. What is the SEC CIK of Phio Pharmaceuticals? The SEC Central Index Key (CIK) for Phio Pharmaceuticals Corp. is 1533040. Its filings are on SEC EDGAR. How many shares does Phio Pharmaceuticals have outstanding? 11,617,250 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Phio Pharmaceuticals listed under? Our directory records Phio Pharmaceuticals Corp. under United States. What does Phio Pharmaceuticals do? Our directory classifies Phio Pharmaceuticals Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Phio Pharmaceuticals? The ISIN recorded for Phio Pharmaceuticals Corp. is US71880W5013. Does aibio.space cover Phio Pharmaceuticals? aibio.space lists Phio Pharmaceuticals Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Phio Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Phio Pharmaceuticals develop? Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL small interfering RNA gene silencing technology. INTASYL compounds are chemically modified siRNAs designed to silence genes that tumors use to evade the immune system, and the company says they can be delivered to a broad range of cell types without specialized formulations or delivery systems. What is PH-762 from Phio Pharmaceuticals? PH-762: INTASYL compound designed to reduce PD-1 expression, given by intratumoral injection Stage: Phase 1b trial fully enrolled November 2025; FDA submission targeted second quarter 2026. What is PH-894 from Phio Pharmaceuticals? PH-894: INTASYL compound designed to silence BRD4 in T cells and tumor cells Stage: IND-enabling studies completed; IND submission deferred. Is Phio Pharmaceuticals profitable? Phio Pharmaceuticals Corp. reported a net loss of $8.7 million for the fiscal year ended Dec 31, 2025, and used $8.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Phio Pharmaceuticals Members talk about Phio Pharmaceuticals (PHIO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Phio Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-04-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533040/000143774926011761/phio20260402_8k.htm) 2. 2026-03-05 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm) 3. 2025-11-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/phio20251029_8k.htm) 4. 2025-04-22 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1533040/000168316825002725/phio_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PHIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-PHIO/). ## SEC filings and registration - **SEC name**: Phio Pharmaceuticals Corp. - **CIK**: 1533040 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PHIO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 411 SWEDELAND ROAD, KING OF PRUSSIA, PA, 19406 - **Phone**: (508) 767-3861 - **Shares outstanding**: 11,617,250 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: RXi Pharmaceuticals Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1533040/000143774926032505/phio20261008_8k.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1533040/000143774926031337/phio20260916_8k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/phio20260911_8k.htm) filed 2026-09-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1533040/000143774926027997/phio20251226_def14a.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/phio20260519_8k.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1533040/000143774926026271/phio20260630_10q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/phio20260717_8k.htm) filed 2026-07-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1533040/000143774926015604/phio20260331_10q.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001533040), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Phio Pharmaceuticals Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PHIO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Phio Pharmaceuticals Corp. - **Ticker**: PHIO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US71880W5013 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PHIO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/phio-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Phio Pharmaceuticals (PHIO) news: going concern and offering", 2026-10-31, https://aibio.space/companies/phio-pharmaceuticals/